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Abstract
HIV-associated neurocognitive disorders (HAND) persist in the era of effective combined
antiretroviral therapy (cART). A large body of literature suggests that mitochondrial
dysfunction is a prospective etiology of HAND in the cART era. While viral load is often
suppressed and the immune system remains intact in HIV+ patients on cART, evidence
suggests that the central nervous system (CNS) acts as a reservoir for virus and low-level
expression of viral proteins, which interact with mitochondria. In particular, the HIV
proteins glycoprotein 120, transactivator of transcription, viral protein R, and negative
factor have each been linked to mitochondrial dysfunction in the brain. Moreover, cART
drugs have also been shown to have detrimental effects on mitochondrial function.
Here, we review the evidence generated from human studies, animal models, and
in vitro models that support a role for HIV proteins and/or cART drugs in altered
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production of adenosine triphosphate, mitochondrial dynamics, mitophagy, calcium
signaling and apoptosis, oxidative stress, mitochondrial biogenesis, and immuno-
metabolism in the CNS. When insightful, evidence of HIV or cART-induced mitochon-
drial dysfunction in the peripheral nervous system or other cell types is discussed. Lastly,
therapeutic approaches to targeting mitochondrial dysfunction have been summarized
with the aim of guiding new investigations and providing hope that mitochondrial-
based drugs may provide relief for those suffering with HAND.
1. Introduction
Human immunodeficiency virus (HIV) associated neurological disor-
ders remain prevalent despite the advent of combined antiretroviral therapy
(cART), with as high as 50% of HIV+ patients being afflicted in both the
pre- and post-cART eras (Ellis et al., 2010; Gabbai, Schmidt, Castelo,
Oliveira, & Lima, 1990; Grant et al., 1992; Heaton et al., 2010, 2015).
HIV-associated neurocognitive disorders (HAND) affect approximately
50% of patients on cART and have devastating consequences for patients
and their families (Heaton et al., 2010, 2015). HIV-associated sensory
neuropathy (SN) is the most common HIV-associated neurological disorder
with over 50% of HIV+ individuals being affected (Ellis et al., 2010). This
reviewwill focus onmitochondrial dysfunction as an underlying mechanism
of HAND in the cART era. Studies on the pathogenesis of HIV-SN
may also provide clues into the neuropathogenesis of HIV and cART,
and therefore will be discussed when deemed relevant and insightful.
While the etiology of HAND is likely multifactorial, depending on
both genetic and environmental factors, mitochondrial dysfunction has long
been implicated in HIV-associated neurological disorders, whether the
disorders manifest in the central nervous system (CNS) or in the peripheral
nervous system (PNS) (Estanislao, Thomas, & Simpson, 2004; Gabbai
et al., 1990; Simpson, Chin, Keilbaugh, Lin, & Prusoff, 1989) in pre- and
post-cART eras. Neuropathological analyses of human tissues, animal
models for HAND and in vitro models for HIV-induced neurotoxicity have
shown that HIV, HIV proteins produced by infected cells and ART can all
compromise the function of neuronal mitochondria. Some of the first work
identifying alterations in mitochondria during HIV infection investigated
muscle biopsies from cART naı¨ve HIV+ patients as well as patients on at
least one ART drug (Dalakas, 2001; Dalakas, Semino-Mora, & Leon-
Monzon, 2001; Gabbai et al., 1990; Lewis & Dalakas, 1995). Later work
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using human samples and clinical data used pharmacogenetic approaches
to identify genetic and risk factors for ART-mediated mitochondrial
neurotoxicity. Using animal models for ART-induced neurotoxicity, it
was discovered that some ART drugs, specifically the d-drugs (stavudine,
didanosine, zalcitabine), disrupted mitochondrial DNA (mtDNA) synthesis
and integrity (Lewis & Dalakas, 1995). In part because of this off-target
effect, these drugs are no longer used in clinical practice. Later studies found
alterations to mitochondrial related markers in the brains of HIV+ patients
on cART, although the mechanisms of ART-induced neurotoxicity are
not completely understood and also likely depend on genetic and environ-
mental factors. To study the contribution of HIV and HIV proteins to
HAND, rodent models were developed that expressed HIV proteins in
the brain (Kim et al., 2003; Mucke, Masliah, Rockenstein, & Toggas,
1993; Villeneuve et al., 2016). Others have developed “humanized” mice
that allow for HIV-infection to be recapitulated in vivo. The most relevant,
and most costly, models for HIV-infection involve simian immunodefi-
ciency virus (SIV) infection of rhesus macaques, which have provided
additional evidence for mitochondrial dysfunction as a pathogenic mecha-
nism in HIV-SN (Lehmann, Chen, Borzan, Mankowski, & Hoke, 2011).
However, SIV-induced mitochondrial dysfunction in the CNS has not been
explored. In vitro cellular models have also been valuable tools to help
understand the roles of ART drugs, HIV, and specific HIV proteins in
mitochondrial dysfunction during HAND. Finally, the most recent evi-
dence from the HIV field, and studies of other neurodegenerative diseases
such as Alzheimer’s disease, have revealed evidence that inflammatory stim-
ulation of bystander and immune cells can compromise the bioenergetic
capacity of mitochondria in neurons and thereby cause neurotoxicity. These
mechanisms of mitochondrial dysfunction, as well as the potential targeting
of mitochondria as a therapeutic strategy in HAND, will be discussed
throughout this review.
1.1 HIV neuropathogenesis in pre- and post-cART eras
The neuropathological correlates of HAND have changed drastically since
the widespread use of cART. Prior to the advent of cART, the neuro-
pathogenesis of HIV was characterized by giant multinucleated cells, white
matter myelin pallor and marked loss of neuronal dendrites and synapses
(Gray et al., 1994;Masliah,Miller, & Terry, 1993).While the rate of HAND
diagnosis changed little with the widespread use of cART, HIV associated
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dementia (HAD) was much more prevalent in the pre-cART era (Heaton
et al., 2015). In patients on cART regimens, those with HAND are more
likely to be diagnosed with milder forms of neurocognitive impairment
(NCI) (Heaton et al., 2015). In the cART era, the neuropathology is less
severe and neurotoxicity may be caused by a combination of low-level viral
replication, viral protein production, cART drugs, and chronic inflamma-
tion (Gelman, 2015; Gelman et al., 2012; Levine et al., 2016). While
evidence showed mitochondrial dysfunction may have contributed to
HIV-associated PNS dysfunction in the pre-cART era, there was little evi-
dence of alterations in CNS mitochondrial function. Examination of tissues
from HIV-infected decedents on cART identified alterations in markers for
mitochondrial function and abnormal mitochondria in neurons of the CNS
and PNS as a common characteristic of HIV-associated neurological disor-
ders. Investigations utilizing animal models and in vitro cellular models for
HIV- and ART-associated neurological disorders have vastly increased our
understanding of how mitochondrial dysfunction may play a role in HAND
and HIV-SN in the cART era. Generally, two theories of the etiology of
HAND and HIV-SN remain: (1) the direct model in which HIV, HIV-
proteins, or ART directly alter mitochondrial function in neurons; and
(2) the indirect model, in which bystander cells that have been infected, acti-
vated or damaged by HIV, HIV proteins, or ART disrupt mitochondrial
function in neurons. In this review, we will focus on evidence of mitochon-
drial dysfunction during the cART era by surveying clinical features of
HIV-associated neurological disorders and the published neuropathological
studies of mitochondria in human tissues from decedents on cART. Next,
we will focus on studies of HIV-induced mitochondrial dysfunction as well
as cART-induced mitochondrial dysfunction and how these mechanisms
may underlie HIV-associated neurological disorders. Lastly, we will propose
the next steps to understanding mitochondrial dysfunction in the CNS
during the cART era and how these steps may lead to novel therapeutics
that target mitochondrial dysfunction in the CNS.
1.2 HAND clinical features
HAND describes a clinical diagnosis of cognitive impairment in HIV+
individuals. To make a diagnosis of HAND, HIV+ patients undergo a com-
prehensive neuromedical evaluation that includes assessment of medical
history, structured medical and neurological examinations, and the collection
of blood, cerebrospinal fluid (CSF), and urine samples (Heaton et al., 2010;
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Woods et al., 2004). Clinical data (plasma viral load [VL], postmortem inter-
val, CD4 count, global, learning and motor deficit scores [GDS, LDS, and
MDS]) are also collected.
HAND diagnosis is determined via a comprehensive neuropsychological
test battery, which was constructed to maximize sensitivity to neurocogni-
tive deficits associated with HIV infection. Raw test scores are transformed
into demographically adjusted T-scores, including adjustments for age,
education, gender and race. These demographically adjusted T-scores are
converted to clinical ratings to determine presence and degree of NCI
in seven neurocognitive domains (Woods et al., 2004). As part of the neu-
ropsychological battery, participants complete self-report questionnaires
of everyday functioning: the Lawton and Brody Activities of Daily Living
questionnaire, (Lawton & Brody, 1969), and/or the Patient’s Assessment of
Own Functioning (PAOFI; Chelune & Baer, 1986; Chelune, Heaton, &
Lehman, 1986). Participant’s performance on the neuropsychological test
battery and their responses to the everyday functioning questionnaires are
utilized to assign one of three HAND diagnoses following established criteria
(Antinori et al., 2007). These three categories are HIV-associated asymptom-
atic neurocognitive impairment (ANI), HIV-associated mild neurocognitive
disorder (MND), and HIV-associated dementia (HAD).
The overall rate of HAND diagnoses did not change significantly with
the widespread use of cART. However, the characteristics of HIV infection
and the severity of HAND did change drastically. Pre-cART HAD diag-
noses were around 30%, while ANI and MND made up the other 20%
of all HIV-infected individuals with HAND. After cART implementation,
HAND still affects an estimated 15–50% of HIV+ persons, with the lowest
prevalence in those started on cART early after initial infection and with
sustained viral suppression on ART. HAND persists despite improved
clinical characteristics compared to the HIV+ patients in the pre-cART
era, such as reduced viral load, increased CD4+ cell count, and decreased
co-morbidities. However, studies of CSF and postmortem brain tissues from
HIV+ patients in the post-cART era reveal that certain neuropathological
markers persist. For example, distinct HIV quasispecies isolated from the
CSF of virally suppressed patients suggests that the CNS can act as viral res-
ervoir in patients on suppressive cART (Dahl et al., 2014; Ferretti, Gisslen,
Cinque, & Price, 2015; Lescure et al., 2013). Imaging studies of the brains
of HIV+ infected persons on cART also suggest persisting injury related
to HIV infection (Ances et al., 2010; Ances, Ortega, Vaida, Heaps, &
Paul, 2012). Neurocognitive outcomes often correlate with nuclear and
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mitochondrial DNA (mtDNA) sequences and interactions between the
two in certain populations. Neuropathological studies of postmortem brain
tissues from HIV+ decedents on cART that were diagnosed with HAND
reveal reduced neuronal integrity, astrogliosis, microgliosis, increased
expression of inflammatory cytokines and alterations in mitochondrial
morphology and integrity (Avdoshina et al., 2016; Fields, Serger, Campos,
et al., 2015; Gelman et al., 2012; Solomon et al., 2017; Soontornniyomkij
et al., 2018). It is likely that HAND neuropathogenesis is multifactorial,
including host and viral genetics as well as environmental variables.
Mitochondrial dysfunction may be a common pathway in HAND and there-
fore a promising therapeutic target.
1.3 Mitochondrial dysfunction in neurological disorders
Mitochondria are the powerhouse of the cell due to their role in trans-
forming bioenergetic substrate into usable energy in the form of ATP.
It is now clear that these organelles are also involved in cell signaling activ-
ities, stress responses, apoptosis and likely many other important cellular
events that are responsible for providing neurons with energy substrates.
It is not surprising that alterations in mitochondrial activity, quantity, mass,
recycling and distribution are hallmarks of many brain diseases as the high
energy demand of neurons makes them particularly dependent on a reliable
source of energy. Multiple mechanisms of neurotoxicity appear to be at
work among individuals with HAND, including HIV activation of apo-
ptotic pathways (Kaul, Garden, & Lipton, 2001), dysregulation of calcium
(Ca2+) homeostasis (Gendelman, Lipton, Tardieu, Bukrinsky, & Nottet,
1994; Nath et al., 2000), mitochondrial dynamics, and oxidative stress
(Nath, 2002; Norman et al., 2008). All of these potentially neurotoxic
processes can be buffered by a healthy pool of mitochondria.
To maintain and enrich the pool of healthy mitochondria, cells operate
tightly regulated processes for generating (biogenesis) and transporting new
mitochondria, while degrading damaged mitochondria by a process called
mitophagy (Ventura-Clapier, Garnier, & Veksler, 2008) (Schematic 1).
According to bioenergetic needs, healthy mitochondria are split (mitochon-
drial fission) and distributed throughout the soma, dendrites, and axons to
fuel synapses used for learning, memory and other crucial brain functions
(Nikoletopoulou & Tavernarakis, 2014; Ventura-Clapier et al., 2008).
Damaged portions of the mitochondrial network are tagged for degradation
and then split from healthy mitochondria (more fission) to be recycled
by mitophagy. Disruption of mitochondrial biogenesis, mitochondrial
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transport and/ormitophagy is implicated in several neurodegenerative diseases
including Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s
disease (PD), and HAND (Bonavia et al., 2001; Fields, Dumaop, Eleuteri,
et al., 2015; Fields et al., 2013; Fields, Serger, Campos, et al., 2015;
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Schematic 1 HIV and cART disruption of mitochondrial processes. (1) Mitochondrial
biogenesis is stimulated when energy demands are not being met, which increases
the ratio of AMP:ATP. AMP activates AMPK, which in turn phosphorylates many signal-
ing factors including PGC-1α. PGC-1α enters the nucleus where it, along with other
transcription factors (TF), binds to DNA to produce many mRNAs including TFAM, a
TF involved in mtDNA replication and gene expression. Some ART drugs interfere with
mtDNA replication, leading to damaged mtDNA. (2) Mitochondrial fusion requires,
among other proteins, MFN1, MFN2, and OPA1. HIV proteins gp120 and Tat are involved
in alterations in mitochondrial fusion. (3) Mitochondrial fission requires, among other
proteins, DNM1L and Fis1. HIV proteins gp120 and Tat are involved in alterations in
mitochondrial fission. (4) Damaged mitochondria (red) are tagged for removal and
engulfment by LC3-II-positive autophagosomes, which then fuse to lysosomes to form
autophagolysosomes in a process termed mitophagy. HIV gp120 and Tat have been
shown to alter autophagy and mitophagy in neurons and Tat also alters mitophagy
in microglial cells. (5) To be transported throughout the cell, mitochondria are
linked to adaptor proteins and molecular motors, dynein and kinesin, which drag the
mitochondria along microtubules. HIV gp120 alters mitochondrial transport. (6) The
mitochondrial associated membrane (MAM) is a region of the endoplasmic reticulum
that is in contact, via multiple proteins, to the mitochondrial network. At the MAM,
proteins, lipids, and Ca2+ are delivered to mitochondria. The MAM is implicated in
mitochondrial toxicity due to increased Ca2+ by way of HIV gp120, Tat, Nef, and Vpr.
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Huang, Chiang, Lin, Chiou, & Chow, 2012; Kitayama et al., 2008;
McArthur, Steiner, Sacktor, & Nath, 2010; Repunte-Canonigo et al.,
2014; van der Walt et al., 2003; Wang et al., 2013; Ye, Tai, & Zhang,
2012). Below, we discuss these regulatory mechanisms in more detail.
1.3.1 Mitochondrial alterations in HIV+ brains from the cART era
Mitochondrial dysfunction in the brain during HAND is supported by
direct and indirect evidence ranging from brain imaging studies in HIV+
patients to neuropathological assessments of postmortem brain specimens.
HIV enters the brain early during infection, causing inflammation and
neurodegeneration, which likely increases the metabolic needs of neurons
and glia (Gendelman et al., 1994; Koenig et al., 1986). Some cART drugs
also penetrate the brain parenchyma and studies from the PNS have shown
that these compounds can have profound effects on mtDNA replication and
integrity (Ene, Duiculescu, & Ruta, 2011; Lewis & Dalakas, 1995). Kinases
active in the cell can act on nucleoside reverse transcriptase inhibitors
(NRTI) through phosphorylation steps that generate nucleotide reverse
transcriptase inhibitors, which can then enter mitochondria and compete
with native nucleotides at DNA polymerase active sites and thereby inhibit
mtDNA replication via chain termination. Direct evidence for HIV and
cART-induced mitochondrial dysfunction in the brain includes measures
of mitochondrial related biomarkers and direct visualization of mitochondria
in postmortem brain specimens. Some of the first evidence for HIV and
cART-induced mitochondrial dysfunction in the brain showed reduced
levels of N-acetylaspartate in the white matter of HIV+ patients taking
didanosine and/or stavudine (Schweinsburg et al., 2005). Surprisingly, no
significant changes were found in the gray matter of these patients. Neuro-
pathological studies showed accumulation of mtDNA damage in the frontal
cortex of HAND patients (Zhang et al., 2012), which has implications for
the processes of mitochondrial biogenesis and ATP production. A recent
study found similar markers of mitochondrial damage in a cohort of HIV+
brains that were stratified by use of methamphetamine (Var et al., 2016).
In this study, increased mitochondrial injury in Brodmann area 46 of
frontal cortices was associated with worse neurocognitive function in
HIV+METH individuals (Var et al., 2016). Two additional studies by
the same group showed that cell-free mitochondrial DNA in CSF is associ-
ated with viral rebound, inflammation, and severity of HAND diagnosis
(Perez-Santiago et al., 2016) and also with HIV replication, iron transport
and mild HAND (Mehta et al., 2017). Other studies of postmortem brain
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tissues showed alterations in autophagy, which is required for efficient
recycling of mitochondria, in brains of HIV+ patients with HIVE or
HAND diagnoses (Alirezaei, Kiosses, & Fox, 2008; Fields et al., 2013).
Consistent with recycling of mitochondria, proteins that promote mito-
chondrial fission, DNML1 and Fis 1, were found to be reduced while
proteins that promote mitochondrial fusion, MFN1 and optic atrophy
(OPA) 1, were found to be increased in HAND brains compared to HIV+
brains from decedents that had no diagnosed impairment (Avdoshina et al.,
2016; Fields, Serger, Campos, et al., 2015). Another study using the CNS
HIVAntiretroviralTherapyEffectsResearch (CHARTER)cohort found that
certain mtDNA haplogroups were associated with reduced risk for HAND in
Hispanics (Hulgan et al., 2015). A study investigated 1025 patients in the
CHARTER cohort to characterize the interplay of mtDNA haplogroup
and nuclear genetic associations to HAND status (Smieszek et al., 2018).
The patients were stratified by ethnicity as being either of European-descent,
African-descent, or admixed Hispanic. This study revealed interactions
between nuclear SNPs and mtDNA haplogroups that confer susceptibility
to NCI within the European- and African-descent groups (Smieszek et al.,
2018). This study also revealed an interaction between rs978490 and
haplogroup T, which alters the expression of POLG2, a subunit of the
mtDNA polymerase γ (Smieszek et al., 2018). Collectively, these findings
suggest that mitochondrial DNA replication, integrity and dynamics play a
strong role in HAND. Questions remain as to how alterations in mtDNA
affect mitochondrial biogenesis and contribute to HAND, how mitochon-
drial function and dynamics are affected in different brain cell types and the
interplay between these cells downstream of dysfunctional mitochondria.
Indirect evidence for mitochondrial dysfunction in HAND during the
cART era includes the presence of features that are involved in mitochon-
drial dysfunction in related neurodegenerative diseases such as AD and PD.
For example, amyloid beta (Aβ) accumulation, a hallmark of Alzheimer’s
disease, has been associated with HIV infection of the brain during the
cART era (Ortega & Ances, 2014). Moreover, receptors and cellular pro-
cesses that are involved in clearing Aβ from the brain are altered in HAND
brains (Fields et al., 2018). Aβ is associated with altered mitochondrial bio-
genesis, mitochondrial fission/fusion, mitophagy and increased oxidative
stress through generation of ROS. In support of Aβ-induced mitochondrial
dysfunction in the brain during HIV infection, Green et al. reported Aβ
accumulation as a common pathologic feature of HIV infection (Green
et al., 2005). Later, Achim et al. reported increased levels of Aβ in HIV brain
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tissue, specifically neurons (Achim, Adame, Dumaop, Everall, & Masliah,
2009). Aβ is associated with increased astrogliosis and altered bioenergetics
in neurons ( Jiang & Cadenas, 2014; Yin, Sancheti, Patil, & Cadenas, 2016)
through a mechanism that could plausibly be active in HIV-infected brains.
Triggering receptor on myeloid cells 2 (TREM2) plays an important role in
clearing Aβ from the brain and alterations in TREM2 expression is associ-
ated with HIV and AD (Fields et al., 2018; Gisslen et al., 2019). Regardless
of the stimuli, whether it be Aβ, cART, HIV, age, or a combination of
factors, glial-mediated inflammation persists in HIV+ brains in the cART
era, and may appropriate energy substrate that is needed by neurons ( Jiang &
Cadenas, 2014; Yin et al., 2016).
2. HIV proteins and mitochondrial dysfunction
in the CNS
Even in the era of cART, HIV replication and low-level expression of
HIV proteins in the brain and periphery and the ensuing inflammatory
response are likely to underlie many of the neuronal complications associ-
ated with HIV-infection (Ko et al., 2018; Levine et al., 2016; Tso et al.,
2018). While cART has reduced viral load in the periphery, instances of
distinct virus isolated from CSF (viral escape) and antibodies against HIV
proteins found in the brain provide evidence of low-level viral replication
and HIV protein expression in brains of patients on ART (Ferretti et al.,
2015; Levine et al., 2016; Mukerji et al., 2018). While high levels of
HIV replication in the brain are not detectable in the cART era, antibodies
for HIV proteins and HIV genomic DNA have been found in CSF and in
brains of HIV+ decedents that were on cART (Bachani, Sacktor,
McArthur, Nath, & Rumbaugh, 2013; Ko et al., 2018; Tso et al., 2018).
HIV proteins, such as transactivator of transcription (Tat), glycoprotein
(gp) 120, viral protein (VP) R, and negative factor (Nef ) have been linked
to immune activation, oxidative stress, altered mitochondrial transport,
altered autophagic flux, induction of apoptosis, Ca2+ signaling, and
neurotoxicity (Bansal et al., 2000; Dinkins, Arko-Mensah, & Deretic,
2010; Nath, Conant, Chen, Scott, & Major, 1999; Nath, Padua, &
Geiger, 1995; Piller, Jans, Gage, & Jans, 1998; Rozzi, Avdoshina,
Fields, & Mocchetti, 2018; Sawaya, Khalili, Mercer, Denisova, &
Amini, 1998; Teodorof-Diedrich & Spector, 2018; Thangaraj et al.,
2018; Valcour & Shiramizu, 2004). The involvement of HIV proteins
in mitochondrial dysfunction in the brain was highlighted in a study that
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found alterations in the electron transport chain (ETC), glycolytic pathways,
mitochondrial trafficking proteins and proteins crucial to various energy
pathways in a rat model for HIV-induced neurotoxicity (Villeneuve
et al., 2016).
2.1 Gp120
Glycoprotein 120 (gp120) makes up the tripartite spike of the viral envelope
that is essential for viral infection. On the surface of virions, gp120 is non-
covalently linked to the membrane-spanning gp41. Upon binding to CD4
and a chemokine co-receptor (CCR5 or CXCR4) on the host cell, gp120
facilitates fusion of the viral and host cell membranes and deposition of the
viral capsid into the cytoplasm (Deng et al., 1996). Antagonists of gp120
binding and the fusion process inhibit HIV infection (Scarlatti et al., 1997).
Gp120 was one of the first HIV proteins shown to be toxic. Although
neurons do not express CD4, they express both CCR5 and CXCR4,
through which gp120 in the picomolar range induces neurotoxicity
in vitro (Bachis, Major, & Mocchetti, 2003; Lipton, Sucher, Kaiser, &
Dreyer, 1991; Meucci & Miller, 1996). Other studies have shown that
gp120 enters the cytoplasm through multiple mechanisms and can bind
directly to cellular machinery and induce neurotoxicity (Berth, Caicedo,
Sarma, Morfini, & Brady, 2015). A transgenic (tg) mouse model that
expresses gp120 in astrocytes via the glial fibrillary acidic protein (GFAP)
promoter showed evidence of neurotoxicity and neuropathological features
that resemble those observed in the brains of HAND decedents, such as
simplified neuronal processes (Toggas et al., 1994) and loss of dendritic spines
(Bachis,Wenzel, Boelk, Becker, &Mocchetti, 2016).More recent subcellular
neuropathological examination and functional assays of in vitro and in vivo
models have revealed that gp120 has profound effects on neuronal mitochon-
drial dynamics, mitophagy, and apoptosis (Avdoshina et al., 2016; Fields
et al., 2013; Pandhare, Dash, Jones, Villalta, & Dash, 2015; Shah, Kumar,
Simon, Singh, & Kumar, 2013; Teodorof-Diedrich & Spector, 2018).
2.1.1 Gp120 and mitochondrial dynamics
Recent studies using in vitro and in vivo models have shown that gp120 can
have robust effects on mitochondrial fission/fusion and transport in neurons.
Aside from receptor-mediated neurotoxicity, gp120 can be internalized by
PNS and CNS neurons (Bachis et al., 2003; Berth et al., 2015). Once inside
the neuronal cytoplasm, gp120 binds to neuronal specific tubulin β III and is
transported both anterogradely and retrogradely and alters the transport of
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mitochondria in neuronal processes (Avdoshina et al., 2016). Another study
found that rat neurons exposed to gp120 recombinant protein or to condi-
tioned media from monocyte derived macrophages that were exposed to
gp120 exhibited impaired movement of mitochondria (Meeker, Poulton,
Clary, Schriver, & Longo, 2016). These gp120-induced alterations in mito-
chondrial transport could explain the dendritic simplicity and neurotoxicity
observed in gp120 tg mice and neurons in vitro (Bennett, Rusyniak, &
Hollingsworth, 1995; Lipton, Brenneman, Silverstein, Masliah, & Mucke,
1995; Mucke et al., 1993; Savio & Levi, 1993; Toggas et al., 1994).
Altered mitochondrial morphology has been reported in the brains of
HAND decedents including abnormally elongated mitochondria, damaged
cristae, reduced levels of the mitochondrial fission proteins DNM1L and
Fis1 and increased levels of the mitochondrial fission protein MFN1
(Avdoshina et al., 2016; Fields, Serger, Campos, et al., 2015). Exposing
differentiated SH-SY5Y neuroblastoma cells and primary rat neurons to
recombinant gp120 also produced reductions in DNM1L protein levels
and enlarged mitochondria, both of which are reversed after transduction
with lentivirus that overexpressed DNM1L (Fields, Serger, Campos,
et al., 2015). Similar findings were observed in the mouse model for
HIV-induced neurotoxicity that expresses gp120 in the brain (Avdoshina
et al., 2016; Fields, Serger, Campos, et al., 2015; Toggas et al., 1994).
Lentiviral-mediated gene delivery of DNM1L to the brain of gp120 tg
mice reversed the mitochondrial damage, mitochondrial elongation,
gliosis, and neurodegeneration (Fields, Serger, Campos, et al., 2015). In
a follow-up study using the anti-inflammatory drug FK506 (tacrolimus)
both gliosis and neurodegeneration, but not the mitochondrial alterations,
were ameliorated in gp120 tg mice. These findings suggest that the gp120-
induced mitochondrial alterations may produce neurodegeneration
through proinflammatory pathways (Fields et al., 2016). However, not
all studies on gp120 show the same results regarding mitochondrial fission
and fusion. A recent study reported that gp120 enhanced mitochondrial
fission (Teodorof-Diedrich & Spector, 2018). These differences may be
due to different experimental models. However, that would not explain
the elongated mitochondria that were observed in neuropathological studies
of brain tissues from HIV+ decedents diagnosed with HAND (Avdoshina
et al., 2016; Fields, Serger, Campos, et al., 2015). Due to the importance
of distributing mitochondria throughout the cytoplasm of cells, gp120-
induced alterations inmitochondrial fission/fusion and transport may provide
a promising therapeutic target in HIV+ patients with neurological disorders.
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2.1.2 Gp120 and mitophagy
Gp120was first shown to be associated with altered autophagy in the GFAP-
gp120 tg mouse model, in which the levels of protein markers for autophagy
(LC3, Beclin1, and Cathepsin D) were reduced in tg mice compared to
wild-type littermates (Fields et al., 2013). As mentioned in the section above
on mitochondrial dynamics, mitochondrial fission was also found to be
reduced in the gp120 tg mice. Although, the effects on mitophagy have
not been assessed in these mice, these findings suggest that reduced
autophagy and reduced mitochondrial fission may synergistically contribute
to the elongated and damaged mitochondria observed in the brains of these
animals (Avdoshina et al., 2016; Fields, Serger, Campos, et al., 2015).
Another study in SH-SY5Y neuroblastoma cell culture found that gp120
induced activity of proline oxidase (POX), a mitochondrial inner membrane
metabolic enzyme that catalyzes the first step of proline catabolism
(Pandhare et al., 2015). This study also showed that markers for autophagy
were increased in SH-SY5Y cells along with increased ROS levels, each
of which were reversed by treating the cells with a competitive inhibitor
of POX (Pandhare et al., 2015). The authors concluded that POX and
autophagy were induced as a stress response to gp120-induced neurotoxicity
(Pandhare et al., 2015). In light of the effects of gp120 onDNM1L levels and
mitochondrial fission (Avdoshina et al., 2016; Fields, Serger, Campos, et al.,
2015), it is likely that mitophagy is also affected in these cells. The most
recent study on gp120 and mitophagy showed that gp120 induced mito-
chondrial fragmentation but only incomplete mitophagy in primary human
neuroglial cultures (Teodorof-Diedrich & Spector, 2018). Interestingly, and
somewhat contradictory to previous studies, this study also showed that
gp120 and Tat had similar effects on neuronal mitochondrial dynamics
and autophagy, by increasing mitochondrial fission and increasing accumu-
lation of LC3. The authors of this interesting study concluded that while
the prerequisites of mitophagy were increased by gp120 and Tat, the
delivery of mitochondria to the lysosome was impaired, leading to incom-
plete mitophagy (Teodorof-Diedrich & Spector, 2018). The discrepancies
between studies may reflect use of different model systems, ranging from
mouse in vivo to mouse, rat, and human in vitro models for gp120-induced
neurotoxicity.
2.1.3 Gp120 effects on Ca2+ signaling and apoptosis
Through binding chemokine receptors CCR5 and CXCR4, gp120 induces
apoptotic pathways in neurons (Kaul et al., 2001). Activation of these
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pathways leads to progressive reduction in mitochondrial membrane poten-
tial and release of Ca2+ from the endoplasmic reticulum (Haughey &
Mattson, 2002), increased oxidative stress (Mattson, Haughey, & Nath,
2005), and recruitment of the pro-apoptotic transcription factor p53
(Garden et al., 2004). Gp120 induces caspase-3 proteolytic activity and
mitochondrial release of cytochrome c and cell death in neuronal cultures
(Garden et al., 2002). This gp120-induced apoptosis was blocked by specific
inhibitors of both the Fas/tumor necrosis factor-alpha/death receptor
pathway and the mitochondrial caspase pathway (Garden et al., 2002).
Direct treatment of rat neurons with gp120 recombinant protein or with
conditioned media from gp120-treated monocyte derived macrophages
resulted in delayed accumulation of Ca2+ and decreased Ca2+ clearance from
the cell which was associated with dendritic beading, a sign of neurotoxicity
(Meeker et al., 2016). This toxicity was reversed by a p75 neurotrophin
receptor agonist (Meeker et al., 2016). These findings show that gp120
can directly impact how mitochondria regulate important signaling path-
ways and cell death in neurons.
2.2 Tat
Tat first was shown to induce inflammation and oxidative stress in
non-neuronal cells (Venkatesh, Arens, Subramanian, & Chinnadurai,
1990; Westendorp et al., 1995). However, the ability of Tat to induce
inflammation and neurotoxicity was also observed early in the epidemic
(Sabatier et al., 1991). As it became clear that neuronal dysfunction persisted
despite reduced peripheral viral load in patients on cART, investigators
became more interested in how Tat affects CNS neurons.
HIV Tat, a trans-activator of transcription for viral replication, is one of
the first viral genes expressed by infected cells upon integration of proviral
DNA into the genome of the host cell. Tat is released from infected lym-
phoid cells (Ensoli et al., 1993), monocytic cells (Turchan et al., 2001)
and glial cells (Tardieu, Hery, Peudenier, Boespflug, & Montagnier,
1992), including astroglia (Tornatore, Chandra, Berger, & Major, 1994;
Tornatore, Meyers, Atwood, Conant, & Major, 1994). Tat has been linked
to activation of, and inflammatory gene expression by microglia and
astroglia as well as mitochondrial alterations in microglia, astroglia, and
neurons (Rozzi et al., 2018; Teodorof-Diedrich & Spector, 2018;
Thangaraj et al., 2018). In HIVE brains from the pre-cART era, Tat
was detected in the brains of patients using immunohistochemical methods
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(Del Valle et al., 2000; Hudson et al., 2000). More recently, in brains from
patients that were on cART, Tat-specific antibodies were detected in
the CSF by a sensitive ELISA (Bachani et al., 2013). Hence, Tat cytotox-
icity and pro-inflammatory capacity likely persist in some HIV+ persons
despite adherence to viral suppressive cART regimens. HIV Tat alters
mitochondrial integrity, morphology, dynamics, signaling and recycling
in neurons, but also inflammation, oxidative stress, and mitochondrial
function in glia, which sets the stage for neuroinflammation that persists
in a reservoir of low-level HIV infection.
2.2.1 Tat and mitochondrial dynamics
Mitochondrial dynamics and mitophagy are closely linked as proper
mitochondrial fission is a prerequisite of mitophagy. HIV-Tat impacts
mitochondrial dynamics and mitophagy via direct interactions with mito-
chondria and through interactions with associated proteins, though data
are conflicting. Some of the first evidence for Tat affecting mitophagy came
from studies that showed Tat-induced alterations in neuronal lysosomes.
Lysosomal ability to pump protons was impaired by Tat, which affects
lysosomal size, degradative activity, and fusion to autophagosomes (Hui,
Chen, Haughey, & Geiger, 2012). Tat also binds directly to lysosomal asso-
ciated membrane protein 2 (LAMP2) in neuronal cells and in the brain of
transgenic mice expressing Tat from astroglia (Fields, Dumaop, Eleuteri,
et al., 2015). This interaction between Tat and LAMP2A was shown to alter
lysosomal fusion to autophagosomes in neurons (Fields, Dumaop, Eleuteri,
et al., 2015). The effects of Tat were reversed by rapamycin, which has been
shown to reverse inflammation and mitochondrial alterations in other
models (Fields, Dumaop, Eleuteri, et al., 2015). While these studies do
not show direct interactions with mitochondria, they do provide evidence
for impairment in the process of recycling mitochondria through mitophagy,
which requires functional lysosomes and autophagosomes. Recent studies
have shown that Tat also alters mitophagy, though the findings were not
always consistent with previous studies, possibly due to the use of different
model systems, dose, and time of exposure to Tat.
Mitochondrial fission is a prerequisite of mitophagy, as damaged
portions of mitochondria are pinched apart through the action of the GTPase
DNM1L. HIV-Tat promotes CDK5 localization to the cytoplasm of neurons
and causes hyperphosphorylation of tau (Fields, Dumaop, Crews, et al., 2015).
Interestingly, overexpression of tau leads to mitochondrial elongation and
dysfunction via DNM1L mislocalization (DuBoff, Gotz, & Feany, 2012).
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Tat also impairs mitochondrial fission and reduces the average diameter of
neuronal mitochondria (Rozzi et al., 2018). Tat may function differently
in microglia than in neurons by increasing expression of proteins associated
with mitophagy such as PINK1, PRKN, and DNM1L, but still inhibiting
mitophagy by blocking functional autophagy (Thangaraj et al., 2018). The
most recent study showed that Tat promotesmitochondrial fission and incom-
plete mitophagy in human neurons (Teodorof-Diedrich & Spector, 2018).
2.2.2 Tat and mitophagy
Tat protein was first shown to affect lysosomes in neurons, which
could directly affect autophagy and hence mitophagy. Further support
for Tat-mediated effects on autophagy were observed in the doxycycline-
inducible GFAP-Tat tg mouse model and in mouse primary neurons. In this
study, it was shown that Tat binds to LAMP2 and alters lysosomal fusion to
the autophagosome (Fields, Dumaop, Eleuteri, et al., 2015). These findings
are consistent with the more recent study in which Tat was found to induce
incomplete mitophagy by inhibiting the delivery of the damaged mitochon-
dria to the lysosomal compartment in human neuroglial cultures (Teodorof-
Diedrich & Spector, 2018). Together, these findings provide strong
evidence that Tat affects neuronal autophagy. Tat was also recently shown
to induce defective mitophagy in microglia (Thangaraj et al., 2018). Using
mouse primary microglial cells, it was found that Tat altered mitochondrial
membrane potential and induced the mitophagy signaling proteins PINK1,
PRKN, and DNM1L as well as the autophagy proteins, BECN1, LC3 and
SQSTM1 (Thangaraj et al., 2018). These data suggest that the impact of Tat
on autophagy and mitophagy may not be cell specific, whereas the responses
may be cell specific.
2.2.3 Tat effects on Ca2+ signaling and apoptosis
Tat induces apoptosis through activation of caspases, calcium overload
and oxidative stress (Kruman, Nath, & Mattson, 1998). Recombinant Tat
induced apoptosis and increased mitochondrial membrane potential associ-
ated with retraction of neurites in rat cortical neurons (Perry et al., 2005).
A few years later, mechanistic studies in neuronal cultures showed that
Tat acts by binding ryanodine receptors on mitochondria (Norman et al.,
2008). These Tat-mediated direct insults to mitochondria should be viewed
within the context of the other mechanisms of Tat-induced neurotoxicity
including altered autophagy and mechanisms acting through NMDA
receptors. Tat was shown to potentiate glutamate toxicity through
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phosphorylation of the NMDA receptor in hippocampal neurons causing
Ca2+ efflux (Haughey, Nath, Mattson, Slevin, & Geiger, 2001). Tat also
inactivates cytochrome c and induces permeabilization in mitochondria
isolated from mouse brains (Lecoeur et al., 2012). Using cortical neurons
isolated from mouse brains, Tat induced mitochondrial permeabilization
and increased ROS. However, the mitochondrial permeabilization was
reversed by exposing the neurons to creatine (Stevens, Gawryluk, Hui,
Chen, & Geiger, 2014). As indicated by a mouse model for Tat-induced
neurotoxicity, Tat has devastating effects on neurons and collectively,
these studies suggest that Tat-induced alterations in mitochondria are
likely a causative factor (Kim et al., 2003).
2.3 Vpr and Nef
Vpr and Nef are less well-studied HIV proteins compared to gp120 and Tat.
However, they have been shown to elicit profound effects on CNS
mitochondria. Vpr is packaged in the viron and is important for initial infec-
tion of CD4+ T cells and macrophages (Kogan & Rappaport, 2011). Nef
plays a role in maintaining a persistent state of HIV infection by promoting
the survival of infected cells through downmodulation of cell-surface recep-
tors at the immune synapse (Chaudhry et al., 2005; Das & Jameel, 2005).
Both Vpr and Nef disrupt mitochondrial function in uninfected CNS
cells in vitro and in vivo, implicating them in HIV-induced neurological
dysfunction.
2.3.1 Vpr and mitochondrial dynamics
Several studies support a role for Vpr in disrupting mitochondrial dynamics
and transport along axons, which may accelerate neurodegeneration and
neuronal aging. Though not shown in neurons, it was shown that Vpr
associates with the mitochondrial associated membrane of HEK293 cells
and inhibits expression of MFN2 resulting in small and damaged mito-
chondria (Huang et al., 2012). It is plausible that a similar mechanism occurs
in the CNS. Vpr accumulates in mitochondria, binds to adenine nucleotide
translocator, reduces mitochondrial membrane potential, reduces ATP
production and inhibits mitochondrial transportation in primary mouse
neurons (Kitayama et al., 2008). In a recent study using primary mouse
neurons, Vpr was found to reduce the amount of mitochondrial movement
along axons through association with the adenine nucleotide translocator
(Kitayama et al., 2008; Wang et al., 2017). These alterations were associ-
ated with an increase in biomarkers of aging (Kitayama et al., 2008;
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Wang, Walaas, Sihra, Aderem, & Greengard, 1989). Another study found
RNA transcripts for Vpr in brains of HIV+ patients ( Jones et al., 2007).
This group also found that soluble Vpr caused neuronal apoptosis through
cytochrome c release, p53 induction, and activation of caspase 9 ( Jones
et al., 2007).
2.3.2 Vpr effects on Ca2+ and apoptosis
Vpr was shown to induce apoptosis in several cell types before investigations
began to determine the effects of Vpr on neuronal Ca2+ signaling and apo-
ptosis ( Jacotot et al., 2000; Patel, Mukhtar, Harley, Kulkosky, & Pomerantz,
2002). In neurons, Vpr causes release of cytochrome c, which results in Ca2+
release from ER, and activation of caspases ( Jones et al., 2007).
2.3.3 Nef effects on apoptosis
Nef induced the expression of caspase-3 in cultured human astrocytes,
leading to dose-dependent cell death (Acheampong et al., 2009). In a mouse
model of hyperglycemia, Nef induced production of caspase-3, ROS, and
inflammatory genes (Acheampong et al., 2009). In primary human brain
microvascular endothelial cells, Nef induced the expression of multiple
caspases and apoptosis related genes. Nef has been shown to alter Ca2+
signaling through interactions with the IP3 receptor in T cells, but this
mechanism has not yet been observed in neurons (Manninen & Saksela,
2002). Based on these findings, Nef has the potential to induce cytotoxicity
in multiple types of CNS cells and may be a promising target for therapeutic
intervention (Acheampong et al., 2005).
2.4 HIV proteins and mitochondrial mediated oxidative stress
While oxidative stress in the periphery during HIV-infection has been well
studied, we will focus on HIV-protein-related oxidative stress in the CNS.
As mentioned above in the section on mitophagy, gp120 increased the levels
of ROS in neuroblastoma cells by increasing activity of POX, a metabolic
enzyme located in the mitochondrial inner membrane (Pandhare et al.,
2015). Multiple studies have linked gp120 to increased oxidative stress,
but few have investigated the role of mitochondria in these processes, and
those that do, rarely assess CNS cells (Price, Ercal, Nakaoke, & Banks,
2005; Ronaldson & Bendayan, 2008; Shah et al., 2013). Tat-induced
oxidative stress occurs concomitant with increased ATP production and
mitochondrial membrane potential in rat cortical neurons. However, this
study did not link increased oxidative stress directly to mitochondria and
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these changes required high concentrations (2μg/mL) of Tat (Perry et al.,
2005). Recombinant Nef also increased production of ROS in human
astrocytes and in a mouse model of diabetes (Acheampong et al., 2009).
Despite the paucity of data supporting the idea that HIV-proteins directly
cause mitochondrial-mediated increases in oxidative stress in the CNS,
we hypothesize that such deleterious mechanisms are at work in some cases
and require further studies.
2.5 HIV proteins and immunometabolism
Several studies indicate that upon activating glial cells, HIV proteins induce
metabolic and inflammatory responses ( Jiang & Cadenas, 2014; Lee,
Wollam, & Olefsky, 2018; Van den Bossche, O’Neill, & Menon, 2017;
Yin et al., 2016). The metabolic responses include alterations in ROS,
ATP production, lactate production, oxygen consumption and autophagic
flux. These metabolic changes precede, or are concomitant with, induction
of inflammatory gene expression (Lee et al., 2018; Natarajaseenivasan et al.,
2018; Van den Bossche et al., 2017). This is consistent with a growing body
of evidence indicating that increased activation of glial cells compromises the
bioenergetic substrate pool available to neurons and thereby limits neuronal
bioenergetic capacity ( Jiang & Cadenas, 2014; Yin et al., 2016). Moreover,
microglia, the macrophages of the brain, require shifts in metabolic pathways
to orchestrate immune signaling, which is thought to determine the inflam-
matory state in the brain (Lee et al., 2018; Van den Bossche et al., 2017).
Regarding immunometabolic shifts in astroglia, a recent study showed that
Tat induced alterations in human astrocytes occurs concomitant with
changes in oxygen consumption, ATP production, and lactate production
(Natarajaseenivasan et al., 2018). Moreover, these shifts in metabolism were
associated with neurotoxicity (Natarajaseenivasan et al., 2018). The HIV
protein Nef has been shown to induce the expression of inflammatory cyto-
kines in astrocytes (Liu & Kumar, 2015) and in separate studies, Nef was
shown to alter autophagy in astrocytes (Saribas, Khalili, & Sariyer, 2015),
suggesting a link between the metabolic pathway and the immune response
of activated astroglia. Another study using primary mouse microglia showed
that Tat induces alterations in mitochondrial function, mitochondrial fission
and mitophagy concomitant with increases in inflammatory gene expression
(Thangaraj et al., 2018). Together, these studies suggest that HIV proteins
induce immunometabolic mechanisms in activated astroglia and microglia.
In light of studies from other neurodegenerative diseases such as AD
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( Jiang & Cadenas, 2014; Yin et al., 2016), there is strong evidence that the
chronic activation of glial cells in HIV-infected persons could contribute to
the bioenergetic deficiencies and mitochondrial abnormalities observed in
CNS neurons in HAND patients in the cART era.
3. cART and mitochondrial dysfunction in the CNS
Early after the advent of antiretroviral drugs, alterations in mitochon-
drial function were identified in neurons. However, most studies involved
PNS neurons and were associated with HIV-SN. The nature of cART-
induced mitochondrial dysfunction in the PNS is likely not identical to that
of the CNS. Still, studies from the PNS may provide clues as to how cART
could alter mitochondria in the brain and impede neurocognitive function.
Moreover, pharmacogenetic studies from the PNS and CNS likely have
widespread implications since the nuclear and mtDNA are the same, save
for somatic mosaicism (Freed, Stevens, & Pevsner, 2014) and mutation,
in every organ of the body. We will therefore discuss findings from the
PNS that support cART-induced mitochondrial dysfunction in the context
of the findings in the CNS of HAND brains and studies utilizing cellular
models for the CNS. We will also cover the limited evidence that cART
is affecting mitochondrial function in the CNS. These studies include
pharmacogenetics utilizing DNA and cognitive outcomes from large cohorts
of HIV+ patients and in vitro models.
3.1 Post-cART era human studies
Initial studies determined that ART drugs that inhibit the reverse trans-
criptase required for HIV replication also altered the function of human
mtDNA polymerase γ and damaged mtDNA (Lim & Copeland, 2001;
Martin, Brown, Matthews-Davis, & Reardon, 1994). One study detected
HIV-SN in up to 30% of HIV+ patients that were taking 203-
dideoxyctidine (ddc), a non-azylated dideoxynucleoside analog used to treat
AIDS (Dalakas et al., 2001). Using nerve specimens from HIV+ patients
with ddc-neuropathy compared to HIV+ patients with neuropathy but
never exposed to ddc (Dalakas et al., 2001), axonal degeneration was appar-
ent in all HIV+ samples. However, abnormal and enlarged mitochondria,
excessive vacuolization, electron-dense structures and myelin degeneration
were associated with ddc exposure in axons and Schwann cells (Dalakas
et al., 2001). A later study isolated blood cells from 24 HIVcontrols,
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and 8 HIV+ patients who received cART nucleoside analogs and had
hyperlactatemia (Cote et al., 2002). The ratio of mitochondrial DNA copies
to nuclear DNA was reduced in HIV-infected patients with symptomatic,
nucleoside-related hyperlactatemia, but this resolved after discontinuation
of therapy (Cote et al., 2002). These studies provide evidence that some
cART RT inhibitors alter mtDNA integrity and replication, and hence
may affect mitochondrial biogenesis (Lehmann et al., 2011). The effects
of cART on mitochondria in the CNS remain unexplored.
3.1.1 Pharmacogenetics of cART and mitochondrial dysfunction
Mitochondrial DNA sequence variability is associated with variable risk for
developing HAND and HIV-SN. A case-control led investigation of Adult
AIDSClinical Trials Group (ACTG study 384) and of ACTGHumanDNA
Repository participants, which included 509 total HIV+ subjects, revealed
that mitochondrial haplogroup T was an independent predictor of NRTI-
associated peripheral neuropathy (Hulgan et al., 2005). A separate study of
250 self-identified white, non-Hispanic HIV+ patients reported that mito-
chondrial 4918G polymorphism was associated with increased risk for
cART-associated peripheral neuropathy (Canter et al., 2008). These associ-
ations remained after controlling for age, baseline CD4 count, plasma HIV
RNA level, and NRTI randomization. Another recent study by the same
authors sequenced and analyzed the genome of 384 non-Hispanic black
persons from the ACTG study and found that 33% developed peripheral
neuropathy. Multivariate analyses showed that mtDNA subhaplogroup
L1c was an independent predictor of neuropathy (Canter et al., 2010). This
was the first study showing that an African mtDNA subhaplogroup may
increase risk for HIV-SN. These studies show that mtDNA sequence
may interact with cART, HIV, and environmental factors to alter mito-
chondrial, and ultimately neuronal, function.
Several mutations in nuclear genes have also been associated with
increased susceptibility for developing HIV-SN. Interestingly, the protein
products of these genes have direct or indirect connection to the function
of mitochondria. An investigation of 509 HIV+ participants from the
ACTG 384 study and ACTG Human DNA Repository specimens were
randomized to receive three or four drug antiretroviral therapy with didan-
osine (ddI) plus stavudine (d4T) or zidovudine plus lamivudine, given
with efavirenz, nelfinavir, or both, with up to 3 years of follow-up. This
study found that the C282Y mutation in the hemochromatosis gene were
associated with a reduced risk of HIV-SN during antiretroviral therapy
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(Kallianpur et al., 2006). A recent publication found that polymorphisms in
the genes P2X4R and CAMKK2 are associated with susceptibility to HIV-
SN, possibly through increased production of tumor necrosis factor-alpha
(Gaff et al., 2018). While at first glance this study may not arouse suspicion
of mitochondrial involvement, studies in the CNS have shown that inflam-
matory responses in by-stander cells may utilize energy substrates that would
otherwise be used by neuronal mitochondria (Yin et al., 2016). Coupled
with the finding that expression of chemokine receptors is increased on
cells surrounding cutaneous nerves in patients with HIV-SN (Mountford
et al., 2018), infiltrating immune cells that are part of the inflammatory
response initiated by TNF-α may compromise mitochondrial function in
peripheral neurons. These findings provide additional support for alterations
in immunometabolic mechanisms compromising the mitochondrial func-
tion and bioenergetic capacity of neurons, albeit in the PNS.
Another study of the CHARTER cohort provided evidence that
mtDNA haplogroups have some effect on neurocognitive status in HIV+
individuals (Hulgan et al., 2015). In this study of 1027 HIV+ persons,
72% being on cART regimens, mtDNA haplogroups were assessed along
with NCI. Researchers found using multivariate models that haplogroup
B mtDNA was associated with less NCI among persons of genetically
determined Hispanic ancestry (Hulgan et al., 2015). These findings are
particularly interesting considering that overall HIV+ Hispanics have worse
NCI compared to Caucasions (Marquine et al., 2018). A more recent study
using the CHARTER cohort identified a potential role for interactions
between nuclear single nucleotide polymorphisms and mtDNA haplogroups
in NCI in HIV+ persons (Smieszek et al., 2018). This study included 1025
HIV+ persons with nuclear and mitochondrial genome-wide genotyping
that were assessed for NCI. After assessing how the polygenic effect of
SNPs is influenced by mtDNA haplogroups, the study found evidence of
a significant interaction between the nuclear SNPs en masse and mtDNA
haplogroups in individuals of European-descent and also in those of African
descent (Smieszek et al., 2018). These studies suggest that mtDNA inter-
actions with nuclear DNA and environmental factors may affect mitochon-
drial function in the brain and also neurocognitive outcomes.
3.2 cART induces mitochondrial toxicity using in vitro models
Protease inhibitors have been associated with oxidative stress in several cell
types. A study using SH-SY5Y neuroblastoma cells found that the protease
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inhibitors lopinavir and ritonavir induced mitochondrial damage and ROS
generation followed by apoptosis (Tricarico et al., 2016). A previous study
found that ritonavir protected hippocampal neurons from oxidative stress, but
effects on mitochondria were not reported (Wan & DePetrillo, 2002). Using
primary rat neurons, efavirenz was found to decrease mitochondrial mem-
brane potential and enhance superoxide production, suggesting damage to
the mitochondria (Blas-Garcia et al., 2014). Consistent with these findings,
efavirenz induced a dose-dependent decrease in basal and maximal oxygen
consumption in neuroblastoma (SH-SY5Y) and glioma (U-251MG) cells
(Funes, Blas-Garcia, Esplugues, & Apostolova, 2015). A study by the same
group found that efavirenz promotes inducible nitrogen oxide synthase
expression in glial cells and thereby alters mitochondrial function
(Apostolova et al., 2015). In neurons and glia, efavirenz inhibits mitochon-
drial ETC complex I, while other complexes are inhibited in neurons after
longer exposure to efavirenz (Apostolova et al., 2015). A study focusing on
cART drugs with high CNS penetration found that efavirenz, nevirapine,
abacavir, emtricitabine, zidovudine, darunavir, lopinavir, raltegravir, or
maraviroc caused a reduction in spare respiratory capacity in mitochondria
isolated from striatal nerve terminals of male Long-Evans rats (Stauch,
Emanuel, Lamberty, Morsey, & Fox, 2017). In yet another study, tenofovir
disproxil fumarate, efavirenz, ritonavir, and atazanavir were all found to
reduce mitochondrial membrane potential in rat primary neurons, though
these changes did not correlate with neurotoxicity (Robertson, Liner, &
Meeker, 2012). Collectively, these studies suggest that cART, while exten-
ding the life of HIV+ persons, may contribute to mitochondrial dysfunction
in the CNS of HAND patients.
4. Preventing HIV-induced mitochondrial toxicity
The advent of cART has reduced the severity of HAND but has done
little to alter the prevalence of this HIV-associated comorbidity. The benefit
of cART likely stems from reduced viral load in the periphery and in the
CNS, which also reduces the amount of toxicity produced by HIV proteins,
HIV replication, and the accompanying inflammatory responses. Unfortu-
nately, the mitochondrial related neurotoxicity of cART drugs as well as the
low-level viral replication that occurs in virally suppressed patients repre-
sents an unmet need for viable therapeutics. Clinical trials have produced
underwhelming results. Studies using in vitro and in vivo models for
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HIV-induced neurotoxicity may offer clues for developing therapeutic
strategies to target mitochondria in HIV+ individuals on cART.
Antioxidants have been shown to reduce neuronal apoptosis in in vitro
neuronal models for HIV-induced neurotoxicity (Agrawal, Louboutin,
Reyes, Van Bockstaele, & Strayer, 2006; Pocernich, Sultana, Mohmmad-
Abdul, Nath, & Butterfield, 2005; Rozzi et al., 2014; Turchan et al.,
2003). Since mitochondria are a major producer of oxidative stress, especially
dysfunctional mitochondria, the use of antioxidants may be therapeutic to
HAND or HIV-SN patients. The immunophillin FKBP51 is a mitochondrial
protein that protects cells against oxidative stress (Gallo, Lagadari, Piwien-
Pilipuk, & Galigniana, 2011), and its expression is increased in the brains of
HIV+ individuals (Tatro et al., 2009). FK506, a molecule already approved
for clinical use, binds immunophillins and has shown promising effects
in reducing HIV gp120 associated neurodegeneration and restoring mito-
chondrial homeostasis in the gp120 tg mouse model for HIV-induced
neurotoxicity (Fields et al., 2016). Creatine has been shown to promotemain-
tenance of ATP levels, protect mitochondrial membrane potential, reduce
oxidative stress and be neuroprotective in neurons exposed to Tat protein
(Stevens et al., 2014). Consistent with these findings, blocking uptake of
Tat by heparan sulfate and dextran sulfate reduced mitochondrial dysfunc-
tion in neurons (Chauhan et al., 2003).
Mitochondrial dynamics andmitophagy may present pathways that can be
targeted for therapeutic approaches in HIV+ individuals. Delivery of the
mitochondrial fission geneDNML1 to the brain of the gp120 tgmousemodel
reduced neuroinflammation and neurodegeneration, suggesting that mole-
cules that enhance mitochondrial fission may be protective against gp120
neurotoxicity (Fields, Serger, Campos, et al., 2015). Rapamycin, another
clinically-approved drug, was shown to enhance autophagy and reduce both
neurodegeneration and neuroinflammation in a tgmousemodel that expresses
the Tat protein in the brain (Fields, Dumaop, Eleuteri, et al., 2015).
Brain derived neurotrophic factor (BDNF) has been shown to be
neuroprotective by supporting mitochondrial health. A flavonoid found
in chocolate and green tea, epicatechin, is able to reduce Tat-induced mito-
chondrial dysfunction in neurons, possibly through increasing BDNF
expression (Nath, Bachani, Harshavardhana, & Steiner, 2012). BDNF
also protects neurons exposed to gp120 (Bachis et al., 2003). There is evi-
dence that BDNF enhances mitochondrial biogenesis, mitochondrial trans-
port, and mitochondrial metabolism in the brain (Cheng et al., 2012;
Marosi & Mattson, 2014; Su, Ji, Sun, Liu, & Chen, 2014). Despite these
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promising observations, some studies suggest that BDNF signaling can be
neurotoxic in the brain (Bachis et al., 2016; Bredesen & Rabizadeh,
1997; Singh et al., 2008; Yang et al., 2014). Nevertheless, neurotrophic
factors such as BDNF deserve further exploration as therapeutic agents in
HIV+ individuals.
Therapeutic interventions for mitochondrial dysfunction in antiretrovi-
ral toxic neuropathy have been tested with limited success. Acetyl-L-
Carnitine (ALC) is crucial for normal mitochondrial function as it acts as
an acetyl-group donor in high-energy metabolism and is a transport mole-
cule for free fatty acids (Bremer, 1990). ALC showed promising therapeutic
efficacy in animal models of diabetic neuropathy (Sima et al., 1996) as well as
immunological benefits in HIV infection (Scarpini, Sacilotto, Baron,
Cusini, & Scarlato, 1997). In patients with antiretroviral toxic neuropathy,
ALC improved cutaneous nerve density and was associated with clinical
benefits (Hart et al., 2004). However, ALC was unsuccessful in alleviating
HIV DSP symptoms in a small open-label study involving 20 patients (Osio
et al., 2006) and in a randomized, placebo-controlled trial of 90 patients
(Youle, 2007). A later open-label, single-arm study showed improvements
in subjective measures of pain whereas changes were not observed in mea-
sures of IENF density or mtDNA levels, providing little objective support
for use of ALC (Valcour et al., 2009).
Immunometabolic mechanisms in activated glia may represent a novel
therapeutic avenue for HAND. Evidence from neurodegenerative diseases
with strong inflammatory signatures in the brain, such as AD, suggests that
reducing activation of infected or uninfected glia may reduce mitochondrial
dysfunction in neurons ( Jiang & Cadenas, 2014; Yin et al., 2016).
Immunometabolic mechanisms in microglia and astroglia are likely playing
a role in HAND and related mitochondrial dysfunction (Fields et al., 2018;
Natarajaseenivasan et al., 2018; Van den Bossche et al., 2017). Hence, ther-
apies that reduce activation of glia may support mitochondrial function in
neurons. Cannabinoid receptor agonists have been shown to be neuro-
protective in animal models for chronic neuroinflammation and HIV-
induced neurotoxicity and also inhibit inflammatory gene expression in glial
cells (Aguirre-Rueda et al., 2015; Avraham et al., 2013; Benard et al., 2012;
Lu et al., 2008; Marchalant, Cerbai, Brothers, & Wenk, 2008; Marchalant,
Rosi, & Wenk, 2007; Martin-Moreno et al., 2012; Sheng et al., 2005).
Moreover, cannabinoid receptor 1 is localized to mitochondria and may
represent a novel therapeutic target in HAND (Navarrete & Araque,
2008; Navarrete, Diez, & Araque, 2014; Robin et al., 2018).
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The one-size-fits all method of prescribing pharmaceuticals was clearly
not productive for HIV+ individuals as many different regimens are used to
different levels of success, not only in different individuals but also during
different times of the infection. A more personalized medicine approach
may also be useful in combating HAND. As pharmacogenetics studies have
illustrated, the genetics of the HIV+ individual can play a role in HIV and
cART interactions and cognitive outcomes. Environmental factors such as
culture, socioeconomic status or geography may also play a role in howHIV
or cART affects mitochondrial function, neurotoxicity and cognitive out-
come (Fields et al., 2018; Marquine et al., 2018; Rubtsova et al., 2018).
Hence, methods to identify personalized treatments involving in vitro assays
that utilize the patients own cells could increase effectiveness of cARTwhile
also reducing interactions with different mtDNA sequences and thereby
reduce neurotoxicity. For example, a study showed that cART can accel-
erate aging of mitochondria by clonal expansion of mutated mtDNA
(Payne et al., 2011). Fibroblasts from patients with mitochondrial diseases
are used to identify deleterious mechanisms and similar methods may pro-
vide insights for personalized treatments for HAND (Ryan et al., 2018).
Studies of HIV and cART-induce mitochondrial dysfunction using cell
models generated from HIV+ patients could provide such an avenue for
treating HAND.
Mitochondrial biogenesis is disrupted in multiple neurodegenerative dis-
eases. Yet no studies, to our knowledge, have investigated this process as a
causative factor in HAND. Mitochondrial biogenesis is linked to metabolic
signaling pathways such as mitochondrial dynamics, autophagy and the
AMPK pathway (Nikoletopoulou & Tavernarakis, 2014; Uittenbogaard &
Chiaramello, 2014). The transcriptional regulators of mitochondrial biogen-
esis are altered in brains of AD and HD patients and increasing mitochondrial
biogenesis by gene deliverymethods can be neuroprotective (Onyango, 2018;
Sheng et al., 2012; Tsunemi et al., 2012; Uittenbogaard & Chiaramello,
2014). Stimulatingmitochondrial biogenesis in neuronsmay represent a novel
therapeutic for HAND and this approach also deserves further investigation.
5. Conclusion
Even with the widespread implementation of effective cART,
HAND remains highly prevalent and mitochondrial dysfunction appears
to play a major role. As the HIV+ population continues to age on long-term
cART, all evidence suggests that disorders of the CNS will only increase.
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As the lifespan of HIV+ individuals increase, comorbidities of aging may
also synergize with those caused by low-level viral replication and neurotox-
icity of cART drugs. The data presented in this review suggest that mito-
chondria, not only in neurons, but also in glia, may represent a promising
target for reducing HAND in the cART era.
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